Skip to content

Inspection Record

Baxter Corporation — Health Canada Inspection Findings

Health CanadaInspected 2026-08-11 7 findingsQuality unit oversightEquipment and facilityDeviation, CAPA, and investigationOther quality systemStability and storageComplaint and recall handlingLabeling and packaging

View the regulator's official source The source document is always the basis for judgement.

Findings

1Quality unit oversight

The annual product quality review procedure was inadequate.

2Equipment and facility

The maintenance of evidence was inadequate for manufacturing, packaging, labelling, required testing, storage, and/or distribution, including the respective conditions. Documents were not available on the premises.

3Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

4Other quality system

The evidence required to demonstrate compliance with finished product specifications was inadequate.

6Complaint and recall handling

The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.

7Labeling and packaging

The positive identification of each batch of drug after the packaging and/or after it was received on the importer's premises was inadequate.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the Health Canada inspection on 2026-08-11. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Baxter Corporation findings history — including this company's other documentsAll Health Canada findings Health Canada documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.